EyeCyte

EyeCyte is a clinical-stage biotechnology company focused on developing autologous cell-based therapies for the treatment of vision-threatening retinal diseases. Founded by researchers from The Scripps Research Institute, the company's lead program utilizes CD34+ cells derived from a patient's own bone marrow to promote vascular repair and neuroprotection in the eye. EyeCyte's pipeline targets conditions such as diabetic retinopathy and retinal vein occlusion by addressing underlying vascular damage. The company was acquired by Aerie Pharmaceuticals in 2020 to bolster their retinal disease portfolio, which was subsequently acquired by Alcon in 2022.